Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen
Author:
- 1 September 2002
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 1 (3) , 253-267
Abstract
The anti-oestrogen tamoxifen, which is widely used as adjuvant therapy for breast cancer, is undergoing evaluation as a chemopreventive agent in women at increased risk of developing this disease. ...Keywords
This publication has 79 references indexed in Scilit:
- Comparative Tolerability of First-Generation Selective Estrogen Receptor Modulators in Breast Cancer Treatment and PreventionDrug Safety, 2001
- Tamoxifen−DNA Adducts Detected in the Endometrium of Women Treated with TamoxifenChemical Research in Toxicology, 1999
- Lack of evidence from HPLC 32P-post-labelling for tamoxifenDNA adducts in the human endometriumCarcinogenesis, 1999
- 4-Hydroxytamoxifen Gives DNA Adducts by Chemical Activation, but Not in Rat Liver CellsChemical Research in Toxicology, 1999
- Chemoprevention of breast cancer — An updateEuropean Journal of Cancer, 1998
- Evaluation of tamoxifen and alpha-hydroxytamoxifen 32P-post-labelled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC methodCarcinogenesis, 1998
- Identification of Tamoxifen−DNA Adducts Formed by α-Sulfate Tamoxifen and α-AcetoxytamoxifenChemical Research in Toxicology, 1997
- Second Cancers After Adjuvant Tamoxifen Therapy for Breast CancerJNCI: Journal of the National Cancer Institute, 1996
- Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patientsCarcinogenesis, 1996
- The Royal Marsden Hospital pilot tamoxifen chemoprevention trialBreast Cancer Research and Treatment, 1994